Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | SHBG | P04278 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20364220 | 1.00 | TSHR (0.56) | TSHRCA1CA2CA4CYP2C9 | |
| SCHEMBL19272821 | 0.97 | TSHR (0.62) | TSHRCA1CA2CA4CYP2C9 | |
| SCHEMBL15906213 | 0.94 | — | — | |
| SCHEMBL1006983 | 0.94 | — | — | |
| SCHEMBL12202956 | 0.90 | TSHR (0.62) | TSHRCA1CA2CA4TDP1 | |
| SCHEMBL4847697 | 0.88 | TSHR (0.59) | TSHRCA1CA2CA4ESR2 | |
| SCHEMBL20461257 | 0.87 | TSHR (0.43) | TSHR | |
| SCHEMBL2193782 | 0.85 | TSHR (0.56) | TSHRCA1CA2CA4TDP1 | |
| SCHEMBL13767338 | 0.85 | TSHR (0.56) | TSHRCA1CA2CA4TDP1 | |
| SCHEMBL328907 | 0.82 | TSHR (0.82) | TSHRCA1CA2CA4ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10357035-B2 | Microbiocidal anilide derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2019-07-23 | — | — | US | disclosed |
| EP-2850121-B1 | HIGH PERFORMANCE POLYSULFONES MADE FROM CYCLOALIPHATIC DIOLS | SOLVAY SPECIALTY POLYMERS USA (US) | 2018-07-11 | — | — | EP | disclosed |
| US-9765176-B2 | Poly(ether ketone) polymers comprising cycloaliphatic units | SOLVAY SPECIALTY POLYMERS USA, LLC (US) | 2017-09-19 | — | — | US | disclosed |
| US-9504753-B2 | Nanometer-sized prodrugs of NSAIDs | CEDARS-SINAI MEDICAL CENTER (US) | 2016-11-29 | — | — | US | disclosed |
| US-20150344610-A1 | POLY(ETHER KETONE) POLYMERS COMPRISING CYCLOALIPHATIC UNITS | SOLVAY SPECIALITY POLYMERS USA, LLC | 2015-12-03 | — | — | US | disclosed |
| WO-2014172663-A1 | NANOMETER-SIZED PRODRUGS OF NSAIDS TO TREAT TRAUMATIC BRAIN INJURY | CEDARS-SINAI MEDICAL CENTER (US) | 2014-10-23 | — | — | WO | disclosed |
| US-8633245-B2 | PAI-1 inhibitor | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2014-01-21 | — | — | US | disclosed |
| US-8304202-B2 | Interaction of BIM with TRIM2 | LEGACY EMANUEL HOSPITAL & HEALTH CENTER (US) | 2012-11-06 | — | — | US | disclosed |
| EP-1710223-B1 | PROCESS FOR PRODUCING ALDEHYDE COMPOUND OR KETONE COMPOUND WITH USE OF MICROREACTOR | UBE INDUSTRIES (JP) | 2012-10-31 | — | — | EP | disclosed |
| EP-2272817-A1 | PAI-1 INHIBITOR | Institute of Medicinal Molecular Design, Inc. (JP) | 2011-01-12 | — | — | EP | disclosed |
| US-20100203552-A1 | INTERACTION OF BIM WITH TRIM2 | LEGACY EMANUEL HOSPITAL & HEALTH CENTER (US) | 2010-08-12 | — | — | US | disclosed |
| US-20090312315-A1 | PAI-1 INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2009-12-17 | — | — | US | disclosed |
| US-20090029925-A1 | INTERACTION OF BIM WITH TRIM2, AN E3 UBIQUITIN LIGASE | LEGACY EMANUEL HOSPITAL & HEALTH CENTER (US) | 2009-01-29 | — | — | US | disclosed |
| US-7332632-B2 | Method for producing aldehyde compound or ketone compound by using microreactor | Ubē Industries, Ltd. (JP) | 2008-02-19 | — | — | US | disclosed |
| US-20070149823-A1 | Method for producing aldehyde compound or ketone compound by using microreactor | UBE INDUSTRIES, LTD., A CORPORATION OF JAPAN (JP) | 2007-06-28 | — | — | US | disclosed |
| EP-1710223-A1 | PROCESS FOR PRODUCING ALDEHYDE COMPOUND OR KETONE COMPOUND WITH USE OF MICROREACTOR | Ube Industries, Ltd. (JP) | 2006-10-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10357035-B2 | Microbiocidal anilide derivatives | MSR1, ARG1, ARG2 | TSHR 2318/4885CA1 2554/4885CA2 1796/4885 |
| US-20090312315-A1 | PAI-1 INHIBITOR | SERPINC1, SERPINE1, SERPINH1 | TSHR 884/4885CA1 2233/4885CA2 2722/4885 |
| US-20070149823-A1 | Method for producing aldehyde compound or ketone compound by using microreactor | ADH1C, ADH1A, ALDH1A1 | TSHR 2363/4885CA1 1026/4885CA2 2767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.